Trial Profile
Impact of a Dolutegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Efavirenz
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms IDEA
- 15 Mar 2022 Status changed from active, no longer recruiting to completed.
- 11 Mar 2021 Planned End Date changed from 1 Mar 2016 to 30 Sep 2021.
- 11 Mar 2021 Planned primary completion date changed from 1 Mar 2016 to 31 Jul 2021.